{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T02:55:08Z","timestamp":1697079308301},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41440-021-00690-6","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T13:03:06Z","timestamp":1626354186000},"page":"1352-1354","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever?"],"prefix":"10.1038","volume":"44","author":[{"given":"Masashi","family":"Mukoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"T35","DOI":"10.1530\/JOE-16-0669","volume":"234","author":"S Shibata","year":"2017","unstructured":"Shibata S. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017;234:T35\u201347.","journal-title":"J Endocrinol"},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"690_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","volume":"42","author":"M Nishimoto","year":"2019","unstructured":"Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019;42:514\u201321.","journal-title":"Hypertens Res"},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"690_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension."},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"690_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA."},{"key":"690_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021;44:489\u201397.","journal-title":"Hypertens Res"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1681\/ASN.2020071041","volume":"32","author":"N Ayuzawa","year":"2021","unstructured":"Ayuzawa N, Fujita T. The mineralocorticoid receptor in salt-sensitive hypertension and renal injury. J Am Soc Nephrol. 2021;32:279\u201389.","journal-title":"J Am Soc Nephrol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00690-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T23:26:34Z","timestamp":1633389994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00690-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00690-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}